The collaboration will focus on the emergency use authorisation, promotion, and sale of proxalutamide for the treatment of Covid-19
Kintor is entitled to receive a total of up to RMB560m ($86.7m). (Credit: Masum Ali from Pixabay.)
Kintor Pharmaceutical has joined forces with Shanghai Fosun Pharmaceutical to commercialise its potential Covid-19 treatment proxalutamide in India and 28 African nations.
The collaboration will focus on the emergency use authorisation applications, promotion, and sales of proxalutamide for the treatment of Covid-19 indication.
Under the terms of the licensing agreement, Fosun will receive exclusive registration and commercialisation rights to proxalutamide in the collaboration regions.
Kintor is entitled to receive a total of up to RMB560m ($86.7m), including RMB110m upfront and development milestone payments, and RMB450m commercialisation milestone payments.
The firm is also eligible to receive not less than 50% of the total operating profit as royalty payments in collaboration regions, based on a tiered structure per the amount of net sales.
Proxalutamide is a nonsteroidal androgen receptor (AR) antagonist, currently under development for the potential treatment of Covid-19, prostate cancer, and breast cancer.
In 2021, the drug granted US Food and Drug Administration (FDA) and the Brazilian Health Regulatory Agency (ANVISA) approval for the Phase 3 clinical studies in Covid-19 patients.
Kintor said that since the outbreak of the Covid-19 pandemic in early 2020, it has been advancing the study on proxalutamide as a potential treatment for Covid-19 indication.
The company is now conducting two registered Phase 3 multi-regional clinical trials (MRCT) of proxalutamide for the treatment of Covid-19 outpatients.
Also, it is conducting one Phase 3 MRCT for Covid-19 inpatients in countries and regions including the United States, South America, including Brazil, the European Union, and Asia.
Kintor Pharmaceutical founder, chairman, and CEO Tong Youzhi said: “The global Covid-19 pandemic continues to infect patients and devastate communities.
“Kintor hopes to accelerate emergency use authorizations for proxalutamide in developing countries severely affected by the pandemic to improve the lives of patients infected with Covid-19.
“With Fosun Pharma Group’s excellent abilities in registration and commercialisation overseas, we hope to achieve win-win in the Collaboration Regions, so that more Covid-19 patients can be benefited from proxalutamide.”